LATEST UPDATES » Vol 24, No. 11, November 2020 – Genetic Studies for Diabetes in Asia: The Key to Precision Medicine       » New Leukaemia Vaccine Developed       » Virus-Free Plants, A Mystery Solved       » New Research Methodology for identifying SARS-CoV-2       » New Hope for Detecting Early Stage Pulmonary Hypertension       » Singapore Company Homage Launches Teleconsultation and Mobile Medicine Programme      
BIOBOARD Issue PDF view/purchase
Vol 24, No. 09, September 2020
Singapore Research Team Reports World's First Case of Jamuar Syndrome and Uncovers the Genetic Abnormality Behind it

Collaboration between doctors at KK Women's and Children's Hospital and geneticists at the Institute of Medical Biology (IMB) of A*STAR led to the diagnosis of the world's first case of Jamuar Syndrome, a disease with epileptic seizures and developmental delays. The team also elucidated the genetic mutations responsible for Jamuar Syndrome.

Novel Ventilator Conceptualized by Singapore Clinicians Provides Efficient and Personalized Breathing Support for COVID-19 patients

The SG-Inspire ventilator was built by Singapore clinician innovators in collaboration with engineers and industry experts. It offers personalized care suited to the breathing needs of each patient.

A New Strategy for Developing Dengue Vaccines

Despite the global public health threat of dengue, it is notoriously difficult to develop an effective vaccine. Researchers from the SMART programme in Singapore may have found a new approach for dengue vaccine development through sequential immunisation.

Discovery of Key Protein Sites on the SARS-CoV-2 Virus that can Potentially Improve COVID-19 Diagnosis and Therapeutics

A collaborative study among medical professionals and scientists from the National Centre for Infectious Diseases (NCID) and A*STAR's Singapore Immunology Network (SIgN) unveiled four crucial epitopes on the crown of the SARS-CoV-2 virus to which patient-derived antibodies can bind.

COVID-19 Vaccine Candidate Approved for Human Clinical Trials in Singapore

LUNAR-COV19, a new COVID-19 vaccine candidate developed by Arcturus Therapeutics Holdings Inc. and Duke-NUS Medical School, could produce immunity at low doses, even only after a single administration.

Novel Discovery Finds Cancer-Inducing DNA Mutations Caused by Bacterial Toxins can be Prevented

A research team from Duke-NUS Medical School has uncovered the new knowledge that colibactin, a bacterial protein derived from intestinal Escherichia coli, is a source of cancer-causing DNA mutation. However, an initial analysis shows that colibactin-induced cancers may be preventable.

New Insights into Mechanism for Epstein-Barr Virus- Associated Stomach Cancer

Researchers from Chiba University, Duke-NUS Medical School and the Agency for Science, Technology and Research (A*STAR) uncover the mechanism behind the relationship between the Epstein-Barr virus and cancer development, including the involvement of epigenetics.

Singapore Researchers Devise a Rapid COVID-19 Test Kit for the Detection of Neutralising Antibodies (NAbs) Against SARS-CoV-2

The SARS-CoV-2 surrogate virus neutralisation test (sVNT) was the fruit of collaborative efforts among Duke-NUS Medical School, NCID, A*STAR IMCB and GenScript Biotech. Its high specificity and sensitivity, and short time period needed to obtain results could make it a preferred alternative to current detection methods.

Proteogenomics: Insights into Lung Adenocarcinoma and Potential Applications in Cancer Research

Researchers employ proteogenomics, a combination of proteomics and genomics, to gain a deeper understanding of the molecular workings of lung adenocarcinoma.

Highly Promising Antibody Treatment for Yellow Fever Formulated by SMART Researchers with Significant Reduction in Production Timeline

A potential post-infection antibody treatment for yellow fever, named TY014, was devised by a multi-disciplinary research team at SMART. TY014 could complement vaccination efforts and reduce the risk and occurrence of yellow fever outbreaks worldwide.

Mid-Afternoon Naps Could Be the Solution to Insufficient Sleep at Night

A study from the National University of Singapore shows that split and continuous sleep schedules both result in similar neurocognitive performance of adolescents - as long as they receive the recommended number of hours of sleep per day.

New Cancer Drug ETC-159 Enters Phase 1B of Clinical Trials

Cancer drug developed in Singapore by Duke-NUS Medical School and the Agency for Science, Technology and Research (A*STAR) with applications in cancer immunotherapy takes its first steps into the next phase of clinical trials.

New Hope for Patients with High-Risk Solid Tumours

Treatment formulated by researchers at the Children's Hospital of Philadelphia (CHOP) demonstrate success in overcoming drug resistance and lesser toxicities for aggressive tumours.

Generating Clean Fuel by Artificial Photosynthesis

Team from the University of Cambridge developed a standalone device that converts sunlight, carbon dioxide and water into a carbon-neutral fuel, without requiring any additional components or electricity.

news Virtual Expo Connect to empower access for international pharma to the world’s largest pharma ingredients market
news WEIPU, AstraZeneca, Huadong Medicine, Saint-Gobain, Baxter, Wuxi AppTec, Henlius, Medtronic and more confirmed to speak at E&L China this December
news Singapore company among the ten winners of Falling Wall Breakthrough of the Year 2020, Science Start-up
news PharmaSources Launches the Export-Driven Event CPhI & P-MEC China E-Trade Season

About Us
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy